Gastrointestinal microbiota and inflammasomes interplay in health and disease: a gut feeling.

Journal: Gut
Published Date:

Abstract

The intricate interplay between the gut microbiota and the GI tract has garnered significant attention, as growing evidence has identified the inflammasome as a crucial yet underexplored master regulator in microbiota-driven diseases. Triggered by a variety of dangers, inflammasomes are supramolecular complexes that regulate immune response. A large number of bacterial-derived inducers have been characterised so far. Although structurally divergent, threats are neutralised by the inflammasome, which is then classified into three families: (1) nucleotide-binding oligomerisation domain, leucine-rich repeat-containing proteins, (2) absent in melanoma 2-like receptors and (3) pyrin. An unbalanced microbiota composition, expressed by a dysbiotic phenotype, might therefore induce undesired inflammasome activation, altering the local host homeostasis. Recent studies on the 'microbiota-inflammasome axis' have uncovered unexpected roles for inflammasome signalling in various types of GI cancer and IBD. Additionally, beyond local gut functions, microbiota influences stress responses and neurological health through aberrant secretion of inflammasome-processed cytokines, linking gut-derived signals to systemic diseases via the vagus nerve and the hypothalamic-pituitary-adrenal axis. Besides the standard experimental approaches, this complex network of interactions is now being addressed by Artificial intelligence, which emphasises the profound impact of the gut microbiota on GI health, cancer progression and brain function, opening new avenues for therapeutic intervention in GI diseases, cancer and neurological disorders. Ultimately, microbiota-inflammasome interactions manage a regulatory framework that influences inflammation, cancer progression and systemic diseases, positioning it as both a mediator and a promising therapeutic target in GI malignancies and systemic diseases of the central nervous system.

Authors

  • Roberto De Luca
    Department of Neurology, Beth Israel Deaconess Medical Center and Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA roberto.negro@irccsdebellis.it rdeluca@bidmc.harvard.edu.
  • Valentina Arrè
    Personalized Medicine Laboratory, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte (BA), 70013, Italy.
  • Stefano Nardone
    Department of Medicine, Beth Israel Deaconess Medical Center and Division of Endocrinology, Harvard Medical School, Boston, MA, USA.
  • Sandra Incerpi
    Department of Sciences, University "Roma Tre", Rome, Italy.
  • Gianluigi Giannelli
    Scientific Direction, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte (BA), 70013, Italy.
  • Pankaj Trivedi
    Department of Experimental Medicine, Sapienza Università di Roma, Rome, Italy.
  • Eleni Anastasiadou
    Department of Clinical and Molecular Medicine, Sapienza Università di Roma, Rome, Italy.
  • Roberto Negro
    Division of Endocrinology, V. Fazzi Hospital, Lecce, Italy.

Keywords

No keywords available for this article.